– Trial sponsored by University Clinic RWTH Aachen investigates personalized treatment approaches with Biotest’s Pentaglobin® in peritonitis patients
– Curetis to provide testing services for different samples from up to 200 patients with its recently launched Unyvero IAI Application for intra-abdominal infections
Amsterdam, the Netherlands, and Holzgerlingen, Germany, August 15, 2017; published at 08:00 am CET — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it has closed a partnership with Biotest AG (Dreieich, Germany). Under the terms of the agreement, Curetis will provide Biotest with in-house testing services using Curetis’ Unyvero IAI cartridge for the diagnosis of intra-abdominal infections. Financial terms were not disclosed.
Curetis’ services will comprise testing for microbial pathogens (bacteria and fungi), toxins, and antibiotic resistance markers for the clinical trial PEPPER (Personalized Medicine with Pentaglobin® after surgical source control in patients with peritonitis). PEPPER is a multicentric, two-arm Phase IIb study to test the immune-modulating effect of Pentaglobin®, an IgM enriched immunoglobulin marketed by Biotest, in patients with secondary peritonitis. The clinical trial is being sponsored by RWTH Aachen and conducted in 12 centers across Germany and Austria. Curetis will test approximately 200 native ascites samples and an equal number of matched positive blood culture samples from the same patients.
The Unyvero IAI Cartridge was launched in April this year and has been developed to support clinicians with the fast and reliable diagnosis of various severe conditions, including peritonitis, cholecystitis and acute pancreatitis. It covers up to 92 bacteria, 13 fungi, 3 toxins and 22 resistance markers, among them Clostridium difficile, Clostridium perfringens, Aeromonas spp. as well as difficult-to-cultivate strains such as Prevotella spp. that are often overlooked in the presence of aerobic / fast-growing microorganisms. It also comprises important antibiotic resistance markers such as Colistin resistance marker mcr-1, Fosfomycin resistance marker fosA3 and Nitroimidazol resistance markers nimA and nimB. Together with the Unyvero System, the IAI Cartridge can process a broad variety of clinical samples including tissue, ascites in positively flagged blood cultures, and gastric juice.
“The PEPPER trial is designed to investigate strategies to personalize immune-modulating approaches in patients with septic shock after postoperative secondary peritonitis,” said Dr. Jörg Schüttrumpf, Head of R&D of Biotest. “With an overall mortality of up to 30%, this condition is one of the most fatal diseases on intensive care units. The Unyvero IAI application will provide us with a highly standardized and rapid way to identify the pathogens in the patients enrolled in the PEPPER trial which we are supporting.”
“We are very pleased that only a few months after market launch of the CE-marked Unyvero IAI Cartridge, Biotest has chosen our solution for this important trial,” said Dr. Achim Plum, CCO of Curetis. “With Sanofi, Cempra and the phase III Amikacin trial, Biotest is now the fourth pharmaceutical company using our cartridges in clinical trials to diagnose and stratify patients. This clearly underlines the value of the Unyvero System for the fast and reliable diagnosis of pathogens, antibiotic resistances and other important clinical markers in serious conditions.”
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
firstname.lastname@example.org or email@example.com
www.curetis.com – www.unyvero.com
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Tel. +1 646 536 7012